TABLE 3

Scheme B: MRTcell as functions of CLint,sec, CLd1 CLd2, ka, and nonlinear metabolism (Km of 10 μM and Vmax of 10 nmol/min). Initial drug concentrations of 100 and 300 μM were used; eq. 2 was used to estimate the MRT.


Cln

CLint,sec

MRTcell (min) at ka = 1 min-1

MRTcell (min) at ka = 30 min-1
CLd1 = CLd2 (0.02 ml/min)
CLd1 = CLd2 (0.5 ml/min)
CLd1 = CLd2 (1 ml/min)
CLd1 = CLd2 (5 ml/min)
CLd1 = CLd2 (0.02 ml/min)
CLd1 = CLd2 (0.5 ml/min)
CLd1 = CLd2 (1 ml/min)
CLd1 = CLd2 (5 ml/min)
μM ml/min
Apical Administration
100 1 24.3* 12.7 12.1 11.8 72.6* 12.4* 11.4 10.7
100 5 19.0* 16.3 16.1 15.9 49.6* 12.4* 11.4 10.8
100 10 22.7* 21.3 21.2 21.1 40.5* 12.4* 11.5 10.9
300 1 53.7* 27.4 27.1 26.9 101* 26.6 26.0 25.4
300 5 38.6* 31.1 30.9 30.8 84.6* 26.7 26.2 25.6
300 10 39.7* 35.9 35.7 35.6 77.1* 26.8 26.3 25.8
Basolateral Administration
100 1 132 17.9 17.0 16.4 131 16.9 16.0 15.6
100 5 136 22.5 21.4 20.7 131 17.1 16.2 15.7
100 10 142 28.0 26.6 25.9 131 17.2 16.3 15.9
300 1 133 41.1 40.5 40.1 132 39.8 38.8 37.8
300 5 139 46.3 45.7 45.4 132 39.9 39.0 38.1
300
10
145
52.2
51.5
51.1
132
40.2
39.3
38.5
  • * Deviating trend: increasing values of CLint,sec failed to increase the MRT